Montana Cannabis: 49 Dispensaries Per 100K, 107% Market Capture, and What Balanced Policy Looks Like

Montana has 557 cannabis dispensaries serving 1.1 million residents — 49.2 per 100,000 people, the highest per-capita density of any state studied. The state had to freeze licensing in 2023 because it was over licensed and won't accept new applicants until 2027. Meanwhile, eight counties have banned recreational sales entirely, creating internal prohibition zones where residents must drive to neighboring counties or hold a medical card just to buy legal cannabis. Adult-use purchases carry a 20-23% total tax burden — above the threshold where most states achieve full black market displacement.

None of that has mattered. Four years after launching adult-use sales on January 1, 2022, Montana's dispensaries generated $326.9 million in retail sales against an estimated total addressable market of $305 million — a 107% capture rate that places Montana alongside Colorado as one of only two states to exceed 100% market capture. The surplus isn't a math error. It's 13.8 million annual tourists visiting Glacier and Yellowstone National Parks, plus cross-border demand from four neighboring states without adult-use cannabis.

The numbers:

• Legal market capture: 107% ($326.9M against $305M resident TAM)
• Black market: Effectively displaced (tourism/border sales exceed resident demand)
• Dispensaries: 557 locations across 103 cities and towns
• Tax burden: 20-23% (state 20% + local 0-3%)
• Retail price: $5.34/gram flower (down 30% from $7.83 at launch)
• Dispensary density: 49.2 per 100K residents

Montana reinforces what the cross-state data keeps showing: black market displacement requires balanced performance across multiple dimensions — price competitiveness, retail density, product quality, transaction convenience, and enforcement. Price dominates (4× weight in the framework), and Montana's flower pricing sits at or below black market levels in a state where geographic isolation makes illicit supply chains expensive. But Montana's extreme dispensary density — 49.2 per 100K, triple what Illinois offers — demonstrates how strong access performance amplifies price competitiveness. Illinois has catastrophic pricing and weak density, capturing 30%. Montana has competitive pricing and saturation density, capturing over 100%. Neither variable alone explains the gap. The interaction does.

The state's four-year dataset also provides another market confirming what every legal jurisdiction shows: consumption patterns consistent with the 1.0 g/day flower-equivalent baseline, rising sales volume despite falling prices, and zero evidence of the population-level attrition that inflated CHS prevalence claims would require.

Market Performance

Montana launched adult-use cannabis sales January 1, 2022. Through December 31, 2025:

Cumulative four-year retail: $1.274 billion. Cumulative tax collections: $216.6 million ($207M adult-use, $9.6M medical).

The headline story isn't total growth — it's the channel migration underneath. Medical sales collapsed 59% from $103.6 million (2022) to $42.7 million (2025) as patients shifted to adult-use purchasing. Adult-use absorbed every dollar of that migration and then some, growing 40% from $202.7 million to $284.2 million over the same period. Medical now represents just 13% of total sales, down from 34% at launch.

This isn't a failing medical program. It's rational consumer behavior. When adult-use dispensaries outnumber medical-only locations 546 to 10, most patients stop bothering with annual card renewal. The patients who remain are those with the strongest economic or regulatory reasons: heavy consumers saving meaningful tax dollars, 18-20 year olds who can't buy recreational, and growers who want four plants instead of two.

Seasonal Pattern:

Montana's sales exhibit a consistent seasonal cycle driven by tourism. Summer months (July-August) peak at $29-30 million monthly, while February valleys hit $23-24 million — a 25% swing that maps almost exactly onto national park visitation patterns. Glacier and Yellowstone together drew 7.95 million visitors in 2024. Those visitors don't just look at geysers.

Total Addressable Market

Montana's TAM represents the full dollar value of cannabis consumption across all channels — dispensaries, black market, cross-border purchases, and home cultivation.

TAM Components:

• Adult population (18+): 870,130 (U.S. Census Bureau, 2024 estimates)
• Participation rate: 18% (NSDUH national average)
• Total resident consumers: 156,623
• Consumption rate: 1.0 g/day flower-equivalent (365 g/year)
• Pre-tax retail price: $5.34/gram (weighted average flower, July 2024–June 2025)
• Resident Total Addressable Market: $305.2 million

Legal capture: $326.9M / $305.2M = 107.1%

A capture rate exceeding 100% means Montana is serving more demand than its resident population generates. Colorado shows the same pattern at 104%. The explanation in both states is identical: geographic monopoly over non-resident demand.

Where the surplus comes from:

Montana shares borders with four states. None offer adult-use cannabis retail:

Montana is the only adult-use cannabis market between the Pacific Coast states and the upper Midwest. A Wyoming resident visiting Yellowstone can legally purchase cannabis in West Yellowstone, Gardiner, or Livingston. An Idaho resident visiting Glacier can buy in Columbia Falls, Whitefish, or Kalispell. There is nowhere else to go.

The tourism numbers make the capture math intuitive. In 2024, 13.8 million nonresident visitors spent approximately $5 billion in Montana. If even 2% of those visitors made a cannabis purchase averaging $40, that's $11 million in additional demand — roughly 3.6% of total sales. The actual figure is likely higher. Dispensary clustering around park gateway communities (8 in Big Sky, 4 in West Yellowstone, 2 in Gardiner, 15 in Whitefish, 13 in Columbia Falls) suggests operators already understand this dynamic.

Market Distribution:

• Legal dispensaries serving residents: ~93% of sales (~$304M)
• Legal dispensaries serving tourists/border: ~7% of sales (~$23M)
• Black market: Functionally displaced

Comparison with other markets:

Montana's capture rate at a 20-23% tax burden challenges the assumption that taxes above 20% necessarily sustain black markets. The key is that pre-tax retail pricing is competitive with or below black market pricing — and in a state with no bordering adult-use markets, illicit supply chains face the same geographic cost penalties that legal operators do. When the price variable is neutral or favorable, extreme dispensary density ensures that virtually every population center has legal access within 15 minutes, eliminating the convenience advantage that sustains illicit markets even when pricing is competitive.

Consumption Validation

Montana's retail price studies, conducted by the Department of Revenue from January 2022 through June 2025, provide product-level weight and pricing data. Pre-rolls are ground flower sold at a premium, so flower consumption includes both categories.

Flower consumption (2025, buds + pre-rolls):

• 2025 total retail sales: $326.9 million
• Buds market share: 41.9% → $136.9 million ÷ $5.34/gram = 25.6 million grams
• Pre-roll market share: 9.6% → $31.0 million ÷ $6.46/gram = 4.8 million grams
• Total flower volume: ~30.4 million grams (67,000 lbs, ~5,580 lbs/month)
• Estimated resident consumers: 156,623 (870,130 adults × 18% NSDUH participation)
• Combined flower share: 51.5%
• Per-resident flower consumption: 0.53 g/day

Note on pricing: The $5.34/gram (buds) and $6.46/gram (pre-rolls) are weighted averages from the most recent retail price study period (July 2024–June 2025). Flower prices declined from $7.83/gram at market launch (March 2022) to current levels over four years. For a full four-year volume calculation, a sliding average would be needed — but the 2025 snapshot uses the most current available pricing.

How Montana compares (flower only):

Montana's 0.53 g/day flower consumption falls squarely within the validated 0.50-0.65 g/day range observed across every legal market studied, matching Ohio and Massachusetts almost exactly. Montana's concentrate market share (36.1%) is the highest of any state studied — substantially above the typical 25-31% range — which means more of the total consumption happens through non-flower products, but the flower-only figure still converges on the cross-market baseline.

This is consistent with the 1.0 g/day flower-equivalent baseline observed across every legal jurisdiction. When concentrates and edibles are converted to flower-equivalent using THC content ratios, total consumption converges on the familiar range regardless of product mix — further evidence that the 1.0 g/day baseline reflects a biological constant in consumption behavior, not an artifact of any single market's product preferences.

Four Years of CHS Evidence

Montana's sales data provides another longitudinal dataset contradicting inflated cannabinoid hyperemesis syndrome prevalence claims.

What CHS at claimed prevalence would produce:

Under Habboushe et al.'s 32.9% prevalence estimate, Montana's estimated 156,623 cannabis consumers would include approximately 51,500 CHS sufferers. At the 87.7% cessation rate documented by Russo et al. (2022), roughly 45,200 consumers would exit the market annually. Their departure — heavy consumers at 4.0 g/day per Russo's clinical characterization — would remove approximately 66 metric tons of flower-equivalent annually from a market moving roughly 30 metric tons of flower alone. The implied volume loss exceeds total flower sales by more than 2x — every year.

What the data actually show:

Four consecutive years of sales growth:

• 2022: $306.3 million
• 2023: $316.9 million (+3.5%)
• 2024: $324.3 million (+2.3%)
• 2025: $326.9 million (+0.8%)

The volume data from the retail price studies is even more definitive. Between early 2022 and mid-2024:

• Flower volume grew 28.6% (3,694 lbs/month → 4,751 lbs/month)
• Concentrate volume doubled (+100%: 306 lbs → 613 lbs)
• Pre-roll volume surged 125% (354 lbs → 797 lbs)
• Edible products nearly doubled in average THC content (43 mg → 82 mg per item)

Every product category showed increasing volume. Prices declined 25-30% across the board. This is the textbook signature of a maturing market expanding access — more consumers buying more product at lower prices. It is the opposite of what population-level CHS attrition would produce.

The growth rate is decelerating (3.5% → 2.3% → 0.8%), which reflects normal market maturation, not demand erosion. Montana's market is approaching steady state — the point at which virtually all addressable demand flows through legal channels and growth tracks population change plus tourism trends rather than black market conversion. Colorado hit this inflection around year 4-5. Montana appears to be arriving at the same place on schedule.

Montana joins Florida (319 weeks of tracked dispensation data), Pennsylvania (7 years of sales growth), Colorado (10 years), and every other tracked market in showing zero evidence of the population-level attrition that CHS at 17-33% prevalence would necessarily produce.

Pricing: 30% Decline in Four Years

Montana's retail price trajectory follows the universal maturation curve observed in every legal market, with a higher starting point reflecting the state's small population, geographic remoteness, and closed licensing system.

By Product Category (January 2022 through June 2025):

Edibles are the outlier — the most price-stable category in every market studied, with just 15.6% total swing over four years. Average THC content per product nearly doubled (43 mg → 82 mg), meaning consumers are buying higher-potency products at roughly the same per-milligram cost.

Product mix evolution tells a deeper story:

The shift from flower to concentrates mirrors every maturing market. Flower's market share erosion from 58% to 42% isn't a demand problem — flower volume increased over this period. Concentrates simply grew faster, doubling in volume while capturing 36% of the market. Pre-rolls nearly doubled their share, driven by the same convenience-seeking behavior observed nationally.

The infused non-edible category is collapsing: revenue crashed 81.8% from ~$285K/month (January 2023) to $52K/month (January 2024), with unit counts dropping 74.5%. This appears to be category extinction rather than temporary decline — topicals and similar products losing shelf space to concentrates and edibles that deliver stronger, more predictable effects.

Retail price comparison:

Montana's $5.34 sits in the middle of the pack — above the fully mature and oversupplied markets but below restricted-access states. The license moratorium limits the supply-side competition that drove Michigan and Oregon to $3/gram wholesale collapse, which is likely why Montana's pricing compression has been more gradual (30% over four years versus Oregon's 60%+ over the same period). Whether this is a feature or a bug depends on perspective: consumers pay more, but operators remain profitable and the market hasn't experienced the wave of bankruptcies devastating less regulated states.

Dispensary Density: 557 Locations in a State of 1.1 Million

Montana's dispensary network is the densest in the country relative to population, and the geographic distribution reveals a market shaped by tourism and county-level politics as much as consumer demand.

Top 10 cities by dispensary count (557 total, as of February 3, 2026):

The density outliers tell the story. Columbia Falls (223 per 100K), Whitefish (167 per 100K), and Big Sky (223 per 100K) all serve populations far larger than their census counts suggest. These are gateway communities — Columbia Falls and Whitefish feed Glacier National Park's 3.2 million annual visitors, while Big Sky is the luxury ski resort connecting to Yellowstone's 4.7 million visitors. When your customer base is measured in millions of annual tourists rather than thousands of residents, 13 dispensaries in a town of 5,829 people makes economic sense.

Great Falls is the anomaly. The state's third-largest city has just 34.5 dispensaries per 100K — well below the statewide average of 49.2. With 60,788 residents, it should have roughly 30 dispensaries to match statewide density. It has 21. This likely reflects Great Falls' position away from major tourist corridors and its more conservative political orientation relative to western Montana's college towns.

The medical-only towns: Ten dispensaries across six communities operate as medical-only — Big Timber, Columbus, Dillon (2), Harlowton, Lewistown (2), Missoula (1), Clinton (1), and Roundup. These are in "red" counties that voted to prohibit adult-use retail under Montana's county opt-out provision. Residents in these areas who want recreational cannabis must drive to the nearest green county or obtain a medical card. The existence of medical-only dispensaries in these towns demonstrates persistent demand that county prohibitions redirect but cannot eliminate.

Large operator presence: Several chains have built significant Montana footprints despite the license moratorium. J N J Management (operating as Bloom) has at least 30+ locations statewide — the single largest retail presence. Elevated operates in at least 15 cities. Seed of Life Labs, Grizzly Pine, Lionheart, and Soulttonix (Euphoria Wellness) each maintain 8-15 locations. This consolidation occurred through acquisition of existing licensees rather than new applications, a pattern the moratorium effectively encouraged.

Tax Structure & Medical Card Economics

Montana's tax architecture creates a meaningful economic incentive for medical cardholders — but the math only works for heavy consumers.

Tax rates (MCA 16-12-310):

Thirty counties have adopted local option taxes, most at the full 3% rate. An adult-use consumer in a 3% county pays 23% total tax; a medical cardholder pays 7%. The 16-percentage-point differential creates the entire medical card value proposition.

Medical card economics (MT Revenue – Cardholder Information):

Break-even analysis (in a 3% local option county):

The break-even point sits around $900-1,000 in annual spending — roughly $75/month or 14 grams per month at $5.34/gram. Consumers spending less than that are better off paying the adult-use tax. This explains the medical market's stabilization at $42.7 million: the remaining cardholders are predominantly those spending enough to justify the card.

Additional medical card benefits beyond tax:

• Home cultivation: 4 mature plants + 4 seedlings (vs. 2 + 2 for recreational)
• Household maximum: 8 mature + 8 seedlings (vs. 4 + 4 recreational)
• Monthly possession limits: 5 ounces (vs. 1 ounce recreational)
• Age access: 18+ with qualifying condition (vs. 21+ recreational)

For consumers spending $1,000+ annually or interested in cultivation, the medical card is a clear economic winner.

Regulatory Context

Montana has operated under a licensing moratorium since the start of adult-use sales. Only medical providers licensed by April 27, 2021 can participate in the adult-use market. SB 27, signed May 5, 2025, extended the freeze through June 30, 2027 and prohibits additional licensed premises — the industry calls it "Freeze the Footprint." New applicants can apply starting July 1, 2027.

This wasn't protectionism — it was a response to a market that was already saturated. With 49.2 dispensaries per 100K, Montana had more per-capita retail density than Colorado, Oregon, or any other state with a functioning market. The governor's own budget office projected that without the freeze, another 500 premises could open. Additional licensing would have created the oversupply conditions that collapsed wholesale prices in open-license states.

Compare with Michigan, which issued unlimited cultivation and retail licenses: wholesale flower at $2.18/gram (production cost floor), mass operator losses, and a market propped up by illegal exports to neighboring prohibition states. Montana froze a saturated market. Michigan let a saturated market keep expanding. The outcomes speak for themselves.

Montana also allows individual counties to opt out of adult-use sales entirely. Eight counties have done so. Medical-only dispensaries continue operating in those counties, and the sales data from opt-out counties — Custer County generating $129-143K/month, Fergus County at $118-126K/month — demonstrates that prohibition doesn't eliminate demand. It redirects it.

Conclusion

Four years into adult-use sales, Montana has achieved what most states promise and few deliver: complete black market displacement with stable operator economics, declining consumer prices, and $216.6 million in tax revenue.

Montana gets right what other states don't: balanced performance across all five displacement variables. Price competitiveness comes first — retail pricing matches or undercuts black market levels in a geographically isolated state where illicit supply chains are expensive. Montana pairs that with the highest per-capita dispensary density of any state studied, strong product quality across six tracked categories, and the natural enforcement advantage of geographic remoteness. Illinois demonstrates the inverse: even moderate density can't compensate for catastrophic pricing. Montana demonstrates the positive case: when pricing is competitive, strong performance on the remaining variables pushes capture past 100%.

When the licensing moratorium lifts in 2027, Montana faces a real test. The moratorium has been the firewall preventing the oversupply death spiral that collapsed Michigan and Oregon. New entrants could expand into underserved areas — Great Falls' 34.5 per 100K density suggests room — but uncapped licensing risks tipping a saturated market into the same wholesale collapse the moratorium was designed to prevent.

The result — 107% capture at 20-23% tax — isn't about any single lever. It's balanced execution across price, density, quality, convenience, and enforcement. That's the formula. Most states get one or two variables right and wonder why the black market persists.